Search research articles
Contact Us
Filters
Showing results (241-250 of 254) with videos related to
Page
of 26
Sort By:
Plos One
|
December 7, 2013
Helicobacter pylori cholesteryl α-glucosides contribute to its pathogenicity and immune response by natural killer T cells
Yuki Ito, Jose Luis Vela, Fumiko Matsumura, et al.
Thoracic Cancer
|
July 17, 2019
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, et al.
Translational Lung Cancer Research
|
May 17, 2023
Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets
Midori Shimada, Hirokazu Taniguchi, Hiroyuki Yamaguchi, et al.
Translational Lung Cancer Research
|
November 7, 2024
Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study)
Shinnosuke Takemoto, Minoru Fukuda, Ryosuke Ogata, et al.
The Oncologist
|
October 1, 2022
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Yusuke Chihara, Takayuki Takeda, Yasuhiro Goto, et al.
Cancer Treatment and Research Communications
|
July 4, 2024
Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer
Kanako Sakaeda, Koji Kurose, Yuki Matsumura, et al.
Thoracic Cancer
|
September 7, 2023
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study
Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, et al.
Advances in Clinical Chemistry
|
January 15, 2023
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
Koji Kurose, Kanako Sakaeda, Minoru Fukuda, et al.
Thoracic Cancer
|
July 9, 2022
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, et al.
British Journal of Cancer
|
September 14, 2020
Overcoming the blood-brain barrier by Annexin A1-binding peptide to target brain tumours
Motohiro Nonaka, Misa Suzuki-Anekoji, Jun Nakayama, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 254) with videos related to
Sort By:
Page
of 26
Plos One
|
December 7, 2013
Helicobacter pylori cholesteryl α-glucosides contribute to its pathogenicity and immune response by natural killer T cells
Yuki Ito, Jose Luis Vela, Fumiko Matsumura, et al.
Thoracic Cancer
|
July 17, 2019
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, et al.
Translational Lung Cancer Research
|
May 17, 2023
Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets
Midori Shimada, Hirokazu Taniguchi, Hiroyuki Yamaguchi, et al.
Translational Lung Cancer Research
|
November 7, 2024
Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study)
Shinnosuke Takemoto, Minoru Fukuda, Ryosuke Ogata, et al.
The Oncologist
|
October 1, 2022
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Yusuke Chihara, Takayuki Takeda, Yasuhiro Goto, et al.
Cancer Treatment and Research Communications
|
July 4, 2024
Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer
Kanako Sakaeda, Koji Kurose, Yuki Matsumura, et al.
Thoracic Cancer
|
September 7, 2023
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study
Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, et al.
Advances in Clinical Chemistry
|
January 15, 2023
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
Koji Kurose, Kanako Sakaeda, Minoru Fukuda, et al.
Thoracic Cancer
|
July 9, 2022
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, et al.
British Journal of Cancer
|
September 14, 2020
Overcoming the blood-brain barrier by Annexin A1-binding peptide to target brain tumours
Motohiro Nonaka, Misa Suzuki-Anekoji, Jun Nakayama, et al.
Page
of 26